Navigation Links
Scripps Research scientist receives $1 million research grant from Novo Nordisk
Date:11/8/2011

JUPITER, FL, November 8, 2011 Andrew Butler, an associate professor in The Scripps Research Institute's Department of Metabolism and Aging, has been awarded one million dollars in funding over the next two years to further his research into a novel protein with the potential to improve the understanding and future treatment of diabetes.

The award is notable in that it comes not from the US National Institutes of Health but from Novo Nordisk, an international healthcare company based in Denmark recognized as a world-leader in diabetes treatment.

The Novo Nordisk Diabetes Innovation Award Program was launched in 2011 to help scientists substantiate early research efforts that could result in new treatment options for diabetes and obesity.

Butler's two-year research project, entitled the "Investigation of a Novel Peptide Hormone in Diabetes Treatment," was selected from more than 80 submitted proposals from US and Canadian research institutions.

The research involves a peptide hormone secreted by the liver called adropin. Animal models have shown that peptide hormones play an important role in regulating glucose levels and fatty acid metabolism and that irregular function of these hormones can have a direct effect on an individual's risk of developing obesity and/or diabetes.

"We were studying animal models of insulin resistance as precursor to type 2 diabetes, when we came across adropin," Butler said. "We found it provocative that this particular peptide hormone was distributed in the brain, liver, and pancreasthree tissues that are of great interest to those of us in the diabetes research field."

Butler noted that adropin seems to play a role in maintaining normal insulin sensitivitywhereby only a relatively small amount of insulin is needed to maintain regular blood glucose levels. In type 2 diabetes, insulin sensitivity is often blunted, which means that the normal amounts of insulin produced by the body are no longer as effective in lowering blood glucose levels.

"What has not been established are the mechanisms and sites of action that effect glucose homeostasis [equilibrium]," he said. "So that's what we're going to spend the next two years finding out with the help of this research grant from Novo Nordisk."

The research will also explore adropin's potential role as a protein-based therapy for treating type 2 diabetes, a chronic disease that affects over 300 million people worldwide, according to the World Health Organization. "Clearly, there is an urgent need to identify new and more effective drugs for treating diabetes," Butler said. "Studying how adropin works in this regard could eventually contribute to this effort."


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Florida scientist awarded $2.2 million grant to study hepatitis C
2. Scripps research scientist wins $3.6 million NIH Method to Extend Research in Time award to study alcoholism in Native Americans
3. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
4. Scripps Research scientists reveal how white blood cell promotes growth and spread of cancer
5. Scripps Research scientists define cellular pathway essential to removing damaged mitochondria
6. Scripps Translational Science Institute joins Jackson Laboratory tumor consortium
7. Scripps Research scientists show how shifts in temperature prime immune response
8. CIRM awards Scripps Research Institute scientists $3.5 million
9. Scripps Research wins more than $2 million to study prostate cancer
10. New lupus drug results from Scripps Research technology
11. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research scientist receives $1 million research grant from Novo Nordisk
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology: